Examining the factors contributing to the association between non-albuminuric CKD and a low rate of kidney function decline in diabetes

Autor: Oyunchimeg Buyadaa, Agus Salim, Jedidiah I. Morton, Karin Jandeleit-Dahm, Dianna J. Magliano, Jonathan E. Shaw

Publikováno v: Therapeutic Advances in Endocrinology and Metabolism, Vol 13 (2022)

Background: Studies have shown that among people with diabetes, those with non-albuminuric chronic kidney disease (CKD) have a slower rate of reduction in renal function than do those with normal renal function. This suggests the presence of protecti

Externí odkaz: https://doaj.org/article/21b5c20589bd45b6947d3cc5f97f0a7a

Oral Supplementation of an Alkylglycerol Mix Comprising Different Alkyl Chains Effectively Modulates Multiple Endogenous Plasmalogen Species in Mice

Autor: Sudip Paul, Aliki A. Rasmiena, Kevin Huynh, Adam Alexander T. Smith, Natalie A. Mellett, Karin Jandeleit-Dahm, Graeme I. Lancaster, Peter J. Meikle

Publikováno v: Metabolites, Vol 11, Iss 5, p 299 (2021)

Plasmalogens or alkenylphospholipids are a sub-class of glycerophospholipids with numerous biological functions and are thought to have protective effects against metabolic disease. Dietary supplementation with alkylglycerols (AKGs) has been shown to

Externí odkaz: https://doaj.org/article/7996790ac9e24e4d96c4cd1a94d5ddba

Post-stroke inhibition of induced NADPH oxidase type 4 prevents oxidative stress and neurodegeneration.

Autor: Christoph Kleinschnitz, Henrike Grund, Kirstin Wingler, Melanie E Armitage, Emma Jones, Manish Mittal, David Barit, Tobias Schwarz, Christian Geis, Peter Kraft, Konstanze Barthel, Michael K Schuhmann, Alexander M Herrmann, Sven G Meuth, Guido Stoll, Sabine Meurer, Anja Schrewe, Lore Becker, Valérie Gailus-Durner, Helmut Fuchs, Thomas Klopstock, Martin Hrabé de Angelis, Karin Jandeleit-Dahm, Ajay M Shah, Norbert Weissmann, Harald H H W Schmidt

Publikováno v: PLoS Biology, Vol 8, Iss 9, p e1000479 (2010)

Ischemic stroke is the second leading cause of death worldwide. Only one moderately effective therapy exists, albeit with contraindications that exclude 90% of the patients. This medical need contrasts with a high failure rate of more than 1,000 pre-

Externí odkaz: https://doaj.org/article/ca15ac39c2024783aa2cc40faf23366a

Adverse renal effects of NLRP3 inflammasome inhibition by MCC950 in an interventional model of diabetic kidney disease

Autor: Jakob A. Østergaard, Jay C. Jha, Arpeeta Sharma, Aozhi Dai, Judy S.Y. Choi, Judy B. de Haan, Mark E. Cooper, Karin Jandeleit-Dahm

Publikováno v: Østergaard, J A, Jha, J C, Sharma, A, Dai, A, Choi, J S Y, De Haan, J B, Cooper, M E & Jandeleit-Dah, K 2022, ' Adverse renal effects of NLRP3 inflammasome inhibition by MCC950 in an interventional model of diabetic kidney disease ', Clinical Science, vol. 136, no. 2, pp. 167-180 . https://doi.org/10.1042/CS20210865
Clinical Science (London, England : 1979)

Activation of nucleotide-binding oligomerization domain-like receptor pyrin domain containing 3 (NLRP3) inflammasome has been reported in diabetic complications including diabetic kidney disease (DKD). However, it remains unknown if NLRP3 inhibition

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ecb74c1c6696820a6519eb2f38a2726e
https://doi.org/10.1042/cs20210865

387-P: Novel Mitochondrial Complex I Modulator Reduces Diabetes-Associated Expression of Inflammation and Fibrosis Markers in Human Proximal Tubular Epithelial Cells

Autor: ARA ABOOLIAN, SOFIA URNER, MICHAEL RODEN, KARIN JANDELEIT-DAHM

Publikováno v: Diabetes. 71

Diabetic kidney disease (DKD) is a chronic microvascular complication of diabetes and accounts for 30-40% of all diabetic patients. Patients with DKD experience a progressive and irreversible decline of renal function until dialysis and kidney transp

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c66d8a380fc7bd9f819fa680c1caa9d8
https://doi.org/10.2337/db22-387-p